CAS NO. |
Products Name |
|
808118-40-3 |
FG-4592 |
more... |
FG-4592 is an HIF α prolyl hydroxylase inhibitor, stabilizes HIF-2 and induces EPO production. Phase 3. |
|
849217-64-7 |
Foretinib (GSK1363089) |
more... |
Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2. |
|
|
|
184475-35-2 |
Gefitinib(AZ-1839) |
more... |
Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
|
|
371242-69-2 |
IC-87114 |
more... |
IC-87114 is a selective PI3Kδ inhibitor with IC50 of 0.5 μM, 58-fold more selective for PI3Kδ than PI3Kγ, and over 100-fold more selective than PI3Kα/β. |
|
943540-75-8 |
JNJ33877605 |
more... |
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. Phase 1. |
|
1022150-57-7 |
SGX-523 |
more... |
SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1. |
|
443797-96-4 |
JNJ7706621 |
more... |
JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1. |
|
1138549-36-6 |
CX5461 |
more... |
CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. |
|